Immune checkpoint inhibitors have not been systematically investigated in PCNSL thus far and the available evidence relies on small case series and anecdotal reports on the use of drugs targeting the PD-1 pathway. The gene discussed is PDCD1; the disease is primary central nervous system lymphoma.